Neither the primary nor metastatic tumor harbored KRAS mutation (codon 12, 13, 59, 61, 117, or 146) according to polymerase chain reaction (PCR) using a reverse sequence-specific oligonucleotide methodology (LSI Medience; Tokyo, Japan), nor BRAF V600E mutation according to real-time PCR (LSI Medience). This evidence concerns the gene BRAF and metastatic neoplasm.